Inhibitory effects of fenofibrate on plasminogen activator inhibitor-1 expression in human endothelial cells

Abstract

The effects of fenofibrate on plasminogen activator inhibitor 1 (PAI-1) expression in human umbilical endothelial cell-derived transformed cell line-ECV 304 cells were investigated. ECV 304 cells were incubated with different concentrations of fenofibrate (0, 10, 50, 100 μmol/L) for 24 h. PAI-1 mRNA and protein was detected by reverse transcription-polymerase chain reaction (RT-PCR) and Western blot respectively. PAI-1 antigenic content of endothelial cells was measured by using ELISA. Fenofibrate could inhibit the PAI-1 mRNA and protein expression and reduce PAI-1 antigenic content dependently. After treatment with fenofibrate (10 μmol/L), the expression levels of PAI-1 mRNA and protein were 0.65±0.05 and 0.96±0.11 respectively, significantly lower than in the control group (0.78±0.03 and 1.21±0.15, respectively,P<0.05). PAI-1 antigenic contents (24.52±8.39) in ECV304 cells treated with 10 μmol/L fenofibrate were significantly lower than those in the control group (6.98±5.12,P<0.05). It was concluded that fenofibrate inhibited the expression of PAI-1 mRNA in ECV304 cells, and reduce the protein expression and the antigenic content of PAI-1, suggesting that fenofibrate may have an antiatherosclerotic effect on endothelial cells by PAI-1 pathway.

Keywords

fenofibrate / PAI-1 / atheroschlerosis / endothelial cells

References

[1] ChienK L, LeeY T, SungF C, et al. . Hyperinsulinemia and related atherosclerotic risk factors in the population at cardiovascular risk: A community-based study. Clinical Chemistry, 1999, 45(6 Pt 1): 838-846

[2] MotojimaK, PetersJ M, GonzalezF J. PPARα mediates peroxisome proliferator-induced transcriptional repression of nonperoxisomal gene expression in mouse. Biochem Biophys Res Commun, 1997, 230(1): 155-158

[3] KanekoT, WadaH, WakitaY, et al. . Enhanced tissue factor activity and plasminogen activator inhibitor-1 antigen in human umbilical vein endothelial cells incubated with lipoproteins. Blood Coagul Fibrinolysis, 1994, 5(3): 385-392

[4] SchonfeldG. The effects of fibrates on lipoprotein and hemostatic coronary risk factors. Atherosclerosis, 1994, 111(2): 161-174

[5] NilssonL, TakemuraT, ErikssonP, et al. . Effects of fibrate compounds on expression of plasminogen activator inhibitor-1 by cultured endothelial cells. Arterioscler Thromb Vasc Biol, 1999, 19(6): 1577-1581

[6] BanfiC, AuwerxJ, PomaF, et al. . Induction of plasminogen activator inhibitor I by the PPARalpha ligand, Wy-14, 643, is dependent on ERK1/2 signaling pathway. Thromb Haemost, 2003, 90(4): 611-619

[7] DurringtonP N, MacknessM I, BhatnagarD, et al. . Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia. Atherosclerosis, 1998, 138(1): 217-225

[8] DeleriveP, Martin-NizardF, ChinettiG, et al. . Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res, 1999, 85(5): 394-402